Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.

MLA

Marazzi, Giuseppe, et al. “Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.” The American Journal of Cardiology, vol. 116, no. 12, Dec. 2015, pp. 1798–801. EBSCOhost, https://doi.org/10.1016/j.amjcard.2015.09.023.

APA

Marazzi, G., Pelliccia, F., Campolongo, G., Quattrino, S., Cacciotti, L., Volterrani, M., Gaudio, C., & Rosano, G. (2015). Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. The American Journal of Cardiology, 116(12), 1798–1801. https://doi.org/10.1016/j.amjcard.2015.09.023

Chicago

Marazzi, Giuseppe, Francesco Pelliccia, Giuseppe Campolongo, Silvia Quattrino, Luca Cacciotti, Maurizio Volterrani, Carlo Gaudio, and Giuseppe Rosano. 2015. “Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.” The American Journal of Cardiology 116 (12): 1798–1801. doi:10.1016/j.amjcard.2015.09.023.